{"pmid":32048501,"title":"[Respiratory support for severe 2019-nCoV pneumonia suffering from acute respiratory failure: time and strategy].","text":["[Respiratory support for severe 2019-nCoV pneumonia suffering from acute respiratory failure: time and strategy].","Respiratory support is a very important technique for saving severe 2019-nCoV pneumonia patients who suffering respiratory failure, which can improve oxygenation, reduce mortality. Therefore, how to reasonable using respiratory support technique is the key point that relating success or failure. In this paper, the authors introduce their experience on treating severe 2019-nCoV pneumonia, it is hopeful for current fighting against 2019-nCoV in China.","Zhonghua Jie He He Hu Xi Za Zhi","Yuan, X","Mu, J S","Mo, G X","Hu, X S","Yan, P","Xie, L X","32048501"],"abstract":["Respiratory support is a very important technique for saving severe 2019-nCoV pneumonia patients who suffering respiratory failure, which can improve oxygenation, reduce mortality. Therefore, how to reasonable using respiratory support technique is the key point that relating success or failure. In this paper, the authors introduce their experience on treating severe 2019-nCoV pneumonia, it is hopeful for current fighting against 2019-nCoV in China."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Yuan, X","Mu, J S","Mo, G X","Hu, X S","Yan, P","Xie, L X"],"date":"2020-02-13T11:00:00Z","year":2020,"_id":"32048501","week":"20207|Feb 10 - Feb 16","doi":"10.3760/cma.j.issn.1001-0939.2020.0010","keywords":["2019-nCoV","Oxygenation","Respiratory failure","Respiratory support"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647236292609,"score":6.7365713,"similar":[{"pmid":32040667,"title":"Critical care management of adults with community-acquired severe respiratory viral infection.","text":["Critical care management of adults with community-acquired severe respiratory viral infection.","With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17-53% of such patients. In addition, novel pathogens including zoonotic coronaviruses like the agents causing Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and the 2019 novel coronavirus (2019 nCoV) are still being identified. Patients with severe RVIs requiring ICU care present typically with hypoxemic respiratory failure. Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza. At present, there are no antiviral therapies of proven efficacy for other severe RVIs. Several adjunctive pharmacologic interventions have been studied for their immunomodulatory effects, including macrolides, corticosteroids, cyclooxygenase-2 inhibitors, sirolimus, statins, anti-influenza immune plasma, and vitamin C, but none is recommended at present in severe RVIs. Evidence-based supportive care is the mainstay for management of severe respiratory viral infection. Non-invasive ventilation in patients with severe RVI causing acute hypoxemic respiratory failure and pneumonia is associated with a high likelihood of transition to invasive ventilation. Limited existing knowledge highlights the need for data regarding supportive care and adjunctive pharmacologic therapy that is specific for critically ill patients with severe RVI. There is a need for more pragmatic and efficient designs to test different therapeutics both individually and in combination.","Intensive Care Med","Arabi, Yaseen M","Fowler, Robert","Hayden, Frederick G","32040667"],"abstract":["With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17-53% of such patients. In addition, novel pathogens including zoonotic coronaviruses like the agents causing Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and the 2019 novel coronavirus (2019 nCoV) are still being identified. Patients with severe RVIs requiring ICU care present typically with hypoxemic respiratory failure. Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza. At present, there are no antiviral therapies of proven efficacy for other severe RVIs. Several adjunctive pharmacologic interventions have been studied for their immunomodulatory effects, including macrolides, corticosteroids, cyclooxygenase-2 inhibitors, sirolimus, statins, anti-influenza immune plasma, and vitamin C, but none is recommended at present in severe RVIs. Evidence-based supportive care is the mainstay for management of severe respiratory viral infection. Non-invasive ventilation in patients with severe RVI causing acute hypoxemic respiratory failure and pneumonia is associated with a high likelihood of transition to invasive ventilation. Limited existing knowledge highlights the need for data regarding supportive care and adjunctive pharmacologic therapy that is specific for critically ill patients with severe RVI. There is a need for more pragmatic and efficient designs to test different therapeutics both individually and in combination."],"journal":"Intensive Care Med","authors":["Arabi, Yaseen M","Fowler, Robert","Hayden, Frederick G"],"date":"2020-02-11T11:00:00Z","year":2020,"_id":"32040667","week":"20207|Feb 10 - Feb 16","doi":"10.1007/s00134-020-05943-5","keywords":["Acute respiratory distress syndrome","Antiviral therapy","Coronavirus","Influenza","Neuraminidase inhibitor"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647215321089,"score":112.48104},{"pmid":32022370,"title":"Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.","text":["Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.","With the current trajectory of the 2019-nCoV outbreak unknown, public health and medicinal measures will both be needed to contain spreading of the virus and to optimize patient outcomes. Although little is known about the virus, an examination of the genome sequence shows strong homology with its better-studied cousin, SARS-CoV. The spike protein used for host cell infection shows key nonsynonymous mutations that might hamper the efficacy of previously developed therapeutics but remains a viable target for the development of biologics and macrocyclic peptides. Other key drug targets, including RNA-dependent RNA polymerase and coronavirus main proteinase (3CLpro), share a strikingly high (>95 %) homology to SARS-CoV. Herein, we suggest four potential drug candidates (an ACE2-based peptide, remdesivir, 3CLpro-1 and a novel vinylsulfone protease inhibitor) that could be used to treat patients suffering with the 2019-nCoV. We also summarize previous efforts into drugging these targets and hope to help in the development of broad-spectrum anti-coronaviral agents for future epidemics.","Chembiochem","Morse, Jared S","Lalonde, Tyler","Xu, Shiqing","Liu, Wenshe Ray","32022370"],"abstract":["With the current trajectory of the 2019-nCoV outbreak unknown, public health and medicinal measures will both be needed to contain spreading of the virus and to optimize patient outcomes. Although little is known about the virus, an examination of the genome sequence shows strong homology with its better-studied cousin, SARS-CoV. The spike protein used for host cell infection shows key nonsynonymous mutations that might hamper the efficacy of previously developed therapeutics but remains a viable target for the development of biologics and macrocyclic peptides. Other key drug targets, including RNA-dependent RNA polymerase and coronavirus main proteinase (3CLpro), share a strikingly high (>95 %) homology to SARS-CoV. Herein, we suggest four potential drug candidates (an ACE2-based peptide, remdesivir, 3CLpro-1 and a novel vinylsulfone protease inhibitor) that could be used to treat patients suffering with the 2019-nCoV. We also summarize previous efforts into drugging these targets and hope to help in the development of broad-spectrum anti-coronaviral agents for future epidemics."],"journal":"Chembiochem","authors":["Morse, Jared S","Lalonde, Tyler","Xu, Shiqing","Liu, Wenshe Ray"],"date":"2020-02-06T11:00:00Z","year":2020,"_id":"32022370","week":"20206|Feb 03 - Feb 09","doi":"10.1002/cbic.202000047","keywords":["2019-nCoV","3CLpro","RdRp","SARS","antiviral agents","coronavirus","spike proteins"],"source":"PubMed","locations":["ACE2-based"],"topics":["General Info"],"weight":1,"_version_":1661359647150309377,"score":100.285194},{"pmid":32100976,"title":"[Airway management of COVID-19 patients with severe pneumonia].","text":["[Airway management of COVID-19 patients with severe pneumonia].","Patients with severe and critical COVID-19 will develop into acute respiratory distress syndrome in a short time. Noninvasive or invasive positive pressure ventilation will be important means for those patients, which will help to improve the clinical cure rate and reduce the mortality. Effective airway management has a great significance to improve respiratory support, reduce complications, and promote rehabilitation.","Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi","32100976"],"abstract":["Patients with severe and critical COVID-19 will develop into acute respiratory distress syndrome in a short time. Noninvasive or invasive positive pressure ventilation will be important means for those patients, which will help to improve the clinical cure rate and reduce the mortality. Effective airway management has a great significance to improve respiratory support, reduce complications, and promote rehabilitation."],"journal":"Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi","date":"2020-02-27T11:00:00Z","year":2020,"_id":"32100976","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.issn.1673-0860.2020.04.001","keywords":["Acute respiratory distress syndrome","Airway","COVID-19","Complications","Mechanical ventilation"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647482707968,"score":96.34047},{"pmid":32077677,"title":"[Management strategy of Novel coronavirus pneumonia in burn and wound care ward].","text":["[Management strategy of Novel coronavirus pneumonia in burn and wound care ward].","The prevention and control of novel coronavirus pneumonia (NCP) has already entered a key period . The patients treated in the burn and wound care ward are susceptible to viral infection because of disease, age and other factors, so it is very important to manage the burn and wound care ward during the prevention and control of NCP epidemic. In this paper, combining with the key clinical problems of prevention and control in hospital during the epidemic period of NCP infection, medical evidence, and clinical and management experience, the author formulates prevention and control management strategy of the author's unit in order to provide reference for prevention and control of burn and wound care ward.","Zhonghua Shao Shang Za Zhi","Li, N","Liu, T M","Chen, H L","Liao, J M","32077677"],"abstract":["The prevention and control of novel coronavirus pneumonia (NCP) has already entered a key period . The patients treated in the burn and wound care ward are susceptible to viral infection because of disease, age and other factors, so it is very important to manage the burn and wound care ward during the prevention and control of NCP epidemic. In this paper, combining with the key clinical problems of prevention and control in hospital during the epidemic period of NCP infection, medical evidence, and clinical and management experience, the author formulates prevention and control management strategy of the author's unit in order to provide reference for prevention and control of burn and wound care ward."],"journal":"Zhonghua Shao Shang Za Zhi","authors":["Li, N","Liu, T M","Chen, H L","Liao, J M"],"date":"2020-02-21T11:00:00Z","year":2020,"_id":"32077677","week":"20208|Feb 17 - Feb 23","doi":"10.3760/cma.j.cn501120-20200210-00050","keywords":["Burns","Epidemic prevention and control","Novel coronavirus pneumonia","Patients' Rooms"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647355830273,"score":92.45448},{"pmid":32173241,"title":"Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.","text":["Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.","Since the emergence of coronavirus disease 2019 (COVID-19) (formerly known as the 2019 novel coronavirus [2019-nCoV]) in Wuhan, China in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 75,000 cases have been reported in 32 countries/regions, resulting in more than 2000 deaths worldwide. Despite the fact that most COVID-19 cases and mortalities were reported in China, the WHO has declared this outbreak as the sixth public health emergency of international concern. The COVID-19 can present as an asymptomatic carrier state, acute respiratory disease, and pneumonia. Adults represent the population with the highest infection rate; however, neonates, children, and elderly patients can also be infected by SARS-CoV-2. In addition, nosocomial infection of hospitalized patients and healthcare workers, and viral transmission from asymptomatic carriers are possible. The most common finding on chest imaging among patients with pneumonia was ground-glass opacity with bilateral involvement. Severe cases are more likely to be older patients with underlying comorbidities compared to mild cases. Indeed, age and disease severity may be correlated with the outcomes of COVID-19. To date, effective treatment is lacking; however, clinical trials investigating the efficacy of several agents, including remdesivir and chloroquine, are underway in China. Currently, effective infection control intervention is the only way to prevent the spread of SARS-CoV-2.","J Microbiol Immunol Infect","Lai, Chih-Cheng","Liu, Yen Hung","Wang, Cheng-Yi","Wang, Ya-Hui","Hsueh, Shun-Chung","Yen, Muh-Yen","Ko, Wen-Chien","Hsueh, Po-Ren","32173241"],"abstract":["Since the emergence of coronavirus disease 2019 (COVID-19) (formerly known as the 2019 novel coronavirus [2019-nCoV]) in Wuhan, China in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 75,000 cases have been reported in 32 countries/regions, resulting in more than 2000 deaths worldwide. Despite the fact that most COVID-19 cases and mortalities were reported in China, the WHO has declared this outbreak as the sixth public health emergency of international concern. The COVID-19 can present as an asymptomatic carrier state, acute respiratory disease, and pneumonia. Adults represent the population with the highest infection rate; however, neonates, children, and elderly patients can also be infected by SARS-CoV-2. In addition, nosocomial infection of hospitalized patients and healthcare workers, and viral transmission from asymptomatic carriers are possible. The most common finding on chest imaging among patients with pneumonia was ground-glass opacity with bilateral involvement. Severe cases are more likely to be older patients with underlying comorbidities compared to mild cases. Indeed, age and disease severity may be correlated with the outcomes of COVID-19. To date, effective treatment is lacking; however, clinical trials investigating the efficacy of several agents, including remdesivir and chloroquine, are underway in China. Currently, effective infection control intervention is the only way to prevent the spread of SARS-CoV-2."],"journal":"J Microbiol Immunol Infect","authors":["Lai, Chih-Cheng","Liu, Yen Hung","Wang, Cheng-Yi","Wang, Ya-Hui","Hsueh, Shun-Chung","Yen, Muh-Yen","Ko, Wen-Chien","Hsueh, Po-Ren"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32173241","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.jmii.2020.02.012","keywords":["2019-nCoV","Acute respiratory disease","Asymptomatic carrier","COVID-19","Coronavirus","SARS-CoV-2","Wuhan pneumonia"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1661456248797659136,"score":88.530334}]}